One stock - now trading under $10 - is set to be the biggest winner [Shield] AN OXFORD CLUB PUBLICATION [Liberty Through Wealth]( THE SHORTEST WAY TO A RICH LIFE Most Important Medical Advance in 100 Years Alexander Green | Chief Investment Strategist | The Oxford Club [Alexander Green] Dear Liberty Through Wealth Reader, On Monday, I sent you an article highlighting what I believe is [the single biggest medical breakthrough since antibiotics](. In case you missed it, here's a quick recap. In short, Artificial Intelligence is being harnessed to create breakthrough drugs no one has ever seen before. In a Wall Street Journal interview this month, Dr. Lloyd Minor, dean of the Stanford University School of Medicine, said: "The drug discovery process is on the cusp of being transformed in ways that will dramatically improve the number of therapies that get to patients ... we'll see a lot of new medicines coming out - and medicines more specific to a disease and an individual rather than medicines that are generic in terms of treatment of everyone who has the disorder." Dr. Minor concludes that AI is "a transformative moment in human history," creating the most radical and "most positive transformation in health care since the introduction of antibiotics." This is going to dramatically alter medicine forever. Keep in mind, creating a new effective drug in the past took up to 10 years and could cost up to $12 billion. But now, with artificial intelligence, it could take months and cost a fraction of that amount. And there is one particular company at the forefront of all of this. It is [the first company to bring an AI-designed drug to clinical trials](. And as a result, Big Pharma is lining up to work with them. - Merck is collaborating with them on three projects that could generate up to $674 million in revenue.
- French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs.
- Bristol Meyers Squibb signed a $1.2 billion partnership with the company. And yet... [the company I'm talking about]( is valued at just over $600 million today. And it trades for less than $10. In other words, these deals have the potential to drive the stock many times higher in the months and years ahead. If you're looking for a great AI stock to own, [I invite you to watch my new presentation detailing the opportunity.]( Sincerely, Alexander [The Oxford Club]( You are receiving this email because you subscribed to Liberty Through Wealth.
Liberty Through Wealth is published by The Oxford Club. To stop receiving special invitations and offers from Liberty Through Wealth, please [click here](.
Please note: This will not impact the fulfillment of your subscription in any way. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Liberty Through Wealth]( © 2023 The Oxford Club, LLC All Rights Reserved
The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#)
North America: [1.800.589.3430](#) | International: [+1.443.353.4334](#) | Fax: [1.410.329.1923](#)
[Oxfordclub.com]( Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.